Cerebrolysin: Porcine Brain Peptide Mixture for Neurorecovery
Mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain protein. Approved in many countries for stroke and dementia; evidence is mixed.
👥 Human studies
- Full name
- Cerebrolysin
- Class
- Neuropeptide mixture
- Half-life
- Variable (heterogeneous mixture)
- Route
- Intramuscular or intravenous
- Developer
- Ever Neuro Pharma (AT)
- Regulatory status
- Approved in ~50 countries (Europe, Asia, Latin America) for stroke, TBI, dementia; not FDA-approved
What it is
Cerebrolysin is a standardised mixture of low-molecular-weight peptides (<10 kDa) and amino acids produced by enzymatic digestion of purified porcine brain protein. It is used clinically for acute stroke, traumatic brain injury (TBI) and various dementias, although evidence quality varies.
How it works
Cerebrolysin components mimic endogenous neurotrophic factors — in pre-clinical models it activates signalling pathways similar to BDNF and GDNF, promoting neuronal survival, synaptogenesis, and neurogenesis.
Proposed clinical mechanisms include reduced excitotoxicity after ischaemia, modulation of amyloid processing, and support of cholinergic neurotransmission in dementia.
What the research shows
Multiple RCTs in stroke (CARS, CASTA) and Alzheimer’s; meta-analyses suggest modest benefit.
Muresanu DF et al. (2016) — CARS ischemic stroke recovery
Muresanu D.F. et al., Stroke 2016;47:151–159. 👥 Human studies
208 ischaemic stroke patients received cerebrolysin or placebo for 21 days starting within 24–72 h after symptom onset.
Improvement on the ARAT motor score at 90 days was greater with cerebrolysin (primary endpoint met).
Limitations: Single trial; effect sizes modest; heterogeneity across studies.
Ruether E. et al. (2001) — mild-moderate Alzheimer disease
Ruether E. et al., Int Clin Psychopharmacol 2001;16:253–263. 👥 Human studies
149 patients with mild-moderate AD received cerebrolysin or placebo for 4 weeks.
ADAS-cog and CIBIC+ scores improved; effects persisted some months after treatment.
Limitations: Short duration; modest effect; newer AD therapies change comparator landscape.
Safety and limitations
Generally well tolerated: dizziness, mild GI upset, occasional injection-site reactions. Theoretical anaphylaxis risk due to porcine origin is rare in practice.
Evidence base is heterogeneous; not approved by FDA or EMA. Supply chain and product consistency depend on manufacturer.